Home | Community | Message Board

Sporeworks
This site includes paid links. Please support our sponsors.


Welcome to the Shroomery Message Board! You are experiencing a small sample of what the site has to offer. Please login or register to post messages and view our exclusive members-only content. You'll gain access to additional forums, file attachments, board customizations, encrypted private messages, and much more!

Shop: Mushroom-Hut Mono Tub Substrate   PhytoExtractum Buy Bali Kratom Powder   Left Coast Kratom Buy Kratom Extract   Kraken Kratom Kratom Capsules for Sale   North Spore North Spore Mushroom Grow Kits & Cultivation Supplies   OlympusMyco.com Olympus Myco Bulk Substrate

Jump to first unread post Pages: 1
Offlinesonoramo
Contaminant
Male User Gallery


Registered: 02/27/19
Posts: 894
Loc: California, baby! Flag
Last seen: 14 hours, 25 minutes
Heart risks, serotonin, and fen-phen: 5 Questions for 5-HT receptor researcher Bryan Roth * 4
    #28473717 - 09/18/23 12:30 PM (7 months, 26 days ago)

Heart risks, serotonin, and fen-phen: 5 Questions for 5-HT receptor researcher Bryan Roth


Roth discusses what we know about drugs that stimulate 5-HT receptors and their effect on the heart.


Original story is from The Microdose email newsletter. Subscribe here.

By: Jane C. Hu, Sep 18, 2023




Bryan Roth got interested in psychedelics by accident. After finishing his biochemistry PhD dissertation on opiate receptors, he started a postdoctoral research fellowship at the National Institutes of Health. There, his advisor suggested he study what was then a little-known group of receptors called 5-hydroxytryptamine (5-HT), or serotonin receptors. Roth’s research led him to two particularly interesting classes of drugs that interact with those receptors: psychedelic drugs, which serve as “agonists” and activate the receptor, and atypical antipsychotic drugs, which do the opposite. His first paper on 5-HT receptors was published in 1984, and he has published dozens of papers on the subject since.

One drug that acts on serotonin is fen-phen, a weight loss drug prescribed to over 18 million people in the 1990s. Physicians noticed that patients taking fen-phen were developing valvular heart disease, a condition that occurs when heart valves are damaged. Some fen-phen users developed symptoms including chest pain and heart murmurs within just a month of taking the medication. The drug also increased the risk of pulmonary hypertension and in 1997 the FDA removed fen-phen from the market. The drugmaker eventually paid $3.75 billion in legal settlements to thousands of people who took the drug. After the fen-phen’s withdrawal, Roth’s research lab began studying the link between valvular heart disease and 5-HT serotonin receptors.

Most psychedelics, including psilocybin, MDMA, LSD, DMT, and mescaline, also act on serotonin receptors. The Microdose spoke with Roth about what we know about drugs that stimulate 5-HT receptors and their effect on the heart.

Your lab published a paper back in 2000 analyzing the binding behavior of fenfluramine, the “fen” in fen-phen, to understand why it’s associated with valvular heart disease. You also posited that other serotonergic medications, which are used to treat psychiatric disorders and migraines, may also put people at higher risk of developing valvular heart disease. Why did you decide to work on that issue?

After fen-phen was withdrawn from the market, that’s when my lab got interested in this area. Why was it that this drug causes valvular heart disease? We found that a metabolite of fenfluramine called norfenfluramine is a very potent serotonin receptor agonist, and that these 5-HT2 serotonin receptors are found at high levels in the heart and other peripheral tissues. We showed that a number of other drugs previously known to induce valvular heart disease in humans also activated the 5-HT2B receptor, and we published that data in 2000. At around the same time, there was a group from the pharmaceutical companies DuPont and Merck that published a similar data set.

We began screening other medications and found that a number of drugs used for treating Parkinson’s disease and migraine headaches also activate the 5-HT2B receptor. We notified the FDA and drug companies. To make a long story short, they ignored our recommendations. A few years later, there were large-scale retrospective clinical studies that showed that the drugs we identified had also caused valvular heart disease in up to 30 percent of patients taking them, and several of those drugs have subsequently been withdrawn from the market as well.

Several psychedelics, including psilocybin, LSD, and MDMA, also bind to serotonin receptors. Should people interested in taking these substances and researchers studying potential treatments using these drugs be concerned about possible heart risks?


As far as I can tell from the FDA’s draft guidance, the agency agrees with us that many psychedelic drugs are serotonergic agonists that have the potential to induce valvular heart disease. The science is solid, and anyone involved in drug discovery has already known this for twenty years. It’s really only news to psychedelic consumers. But if you work for a pharma company, you know this already. Any drug in development is tested against this receptor, and if the drug activates it, they throw it away. It’s well-established as a target to avoid.

It’s a risk, and going forward, clinical trials will need to be designed to determine what is the safe dosing regimen. Psychedelics have never been formally assessed for cardiovascular safety, and they need to be.

Several psychedelics, including psilocybin, LSD, and MDMA, also bind to serotonin receptors. Should people interested in taking these substances and researchers studying potential treatments using these drugs be concerned about possible heart risks?

As far as I can tell from the FDA’s draft guidance, the agency agrees with us that many psychedelic drugs are serotonergic agonists that have the potential to induce valvular heart disease. The science is solid, and anyone involved in drug discovery has already known this for twenty years. It’s really only news to psychedelic consumers. But if you work for a pharma company, you know this already. Any drug in development is tested against this receptor, and if the drug activates it, they throw it away. It’s well-established as a target to avoid.

It’s a risk, and going forward, clinical trials will need to be designed to determine what is the safe dosing regimen. Psychedelics have never been formally assessed for cardiovascular safety, and they need to be.

What would a formal assessment look like, and do you think the FDA will mandate that?

Typically, people might start with animal studies. They’re not particularly predictive of what might happen in humans. In humans, typically what’s done is a clinical trial where they do baseline echocardiograms in all patients, then again midway through therapy and after.

At some point, the FDA is probably going to mandate those sorts of trials be done, but it’s not clear from the current draft guidance if they’re going to mandate that for planned phase 3 clinical trials or not. All those studies have one or two doses of psilocybin. If I were a betting man, I would say there’s little chance that that type of dosing would be an issue, but we still need to do clinical trials. The big concern is with repeated dosing, and lots of people are doing that now with microdosing. That’s extraordinarily risky until the appropriate studies have been done; you’re basically recapitulating the situation that led to fen-phen.

You’ve been studying these receptors for three decades now. Have you noticed any change in how interested people are in this area of work?

In 2018, I gave a Presidential Special Lecture at the Society for Neuroscience conference. There were 10,000 people in the audience.  At the talk, I highlighted my lab’s work on psychedelics, and mentioned that the next day, a postdoc from my lab would present work on the structure of LSD bound with serotonin receptor. That work was subsequently published in Cell and it was a huge finding. Only five people came to his poster. It’s really only been recently that people are interested in this work.

Many studies compare psychedelics’ efficacy in treating mental health issues to the efficacy of selective serotonin reuptake inhibitors, or SSRIs. When SSRIs were first brought onto the market, they were marketed as a drug that could “fix” depression by increasing brain serotonin levels. Do SSRIs have the same risk for valvular heart disease?

They do not. SSRIs don’t interact with serotonin receptors; they interact with a certain serotonin transporter. With a single dose, there is some elevation of brain serotonin, but it’s really peripheral. There have been studies that measure serotonin in people’s blood, and they’ve found that chronic SSRI treatment actually lowers serotonin levels.

No neuropsychiatric disease is due to a single neurotransmitter. That said, SSRIs are effective; they’re not for everybody but as a practicing psychiatrist, I’ve seen some truly remarkable recoveries with SSRIs. When I tell people depression is not a serotonin disease, they might say, ‘Well, then, I shouldn't take an SSRI?’ I would not come to that conclusion. They work — we don’t know why they work, but there’s no question they can be effective. What we know from animal studies and some human data is that SSRIs ultimately enhance plasticity in hippocampal and cortical neurons. That’s been known for 20 years, so they share that with psychedelics. But it’s important to note that every drug causes plasticity: morphine, cocaine, amphetamines, PCP. That’s what drugs do — they change how neurons function and that occurs through plasticity. It’s clear that psychedelics also cause plasticity, but the assumption is that this is in some way related to therapeutic actions. It probably is, but the details are still unclear.

This interview has been edited and condensed for clarity and length.

This is The Microdose, a free newsletter from the U.C. Berkeley Center for the Science of Psychedelics.

Extras: Filter Print Post Top
OfflineDave Bowman
Albert Hoffmans Apprentice
Male User Gallery


Folding@home Statistics
Registered: 08/30/07
Posts: 2,126
Loc: Your Imagination
Last seen: 1 month, 12 days
Re: Heart risks, serotonin, and fen-phen: 5 Questions for 5-HT receptor researcher Bryan Roth [Re: sonoramo]
    #28473723 - 09/18/23 12:39 PM (7 months, 26 days ago)

Been reading more and more about the link between the class psychedelics that work on the 5-HT receptors and links to heart issues.  Feels bad man.

Extras: Filter Print Post Top
Invisibledurian_2008
Cornucopian Eating an Elephant
 User Gallery


Registered: 04/02/08
Posts: 18,037
Loc: Raccoon City
Re: Heart risks, serotonin, and fen-phen: 5 Questions for 5-HT receptor researcher Bryan Roth [Re: Dave Bowman]
    #28473773 - 09/18/23 01:24 PM (7 months, 26 days ago)

Quote:

That’s extraordinarily risky until the appropriate studies have been done; you’re basically recapitulating the situation that led to fen-phen.




You are basically healing the same medical conditions, using a timeless, home remedy from the free market, that is not assumed to result in permanent harm, in microdoses or with a trip sitter.

Or, the expensive pharm you get from an entitled commissar could harm you forever.

We can flip the narrative, regarding what affects conscience, artfulness, and the reward center -- those of us who have to live alongside your human wreckage.

Extras: Filter Print Post Top
OfflineBlue Cthulhu
Undefined
 User Gallery

Registered: 05/27/19
Posts: 816
Loc: With the loons
Last seen: 1 hour, 27 minutes
Re: Heart risks, serotonin, and fen-phen: 5 Questions for 5-HT receptor researcher Bryan Roth [Re: durian_2008] * 1
    #28474167 - 09/18/23 07:32 PM (7 months, 26 days ago)

This issue has come up periodically. I have yet to hear any anecdotal evidence of psychedelic use causing these heart issues. Sounds like it's worth looking into, just to be safe, but... I'm always a bit wary of unsubstantiated alarmism.

Here's a decent Reddit discussion about the topic: https://www.reddit.com/r/microdosing/comments/l1gdgn/re_heart_valve_disease_association_with/

I'm the furthest thing from a pharmacologist. Would be interesting to hear a nuanced debate/discussion between some on this topic.


--------------------
:musicnote:  :royalrainbow:
"Things are true that I forget, but no one taught that to me yet."
A disembodied-re-embodied consciousness be-ing
(With all the accoutrements.)

Extras: Filter Print Post Top
OfflineHappyHigh
Stranger

Registered: 05/05/17
Posts: 897
Last seen: 1 month, 18 days
Re: Heart risks, serotonin, and fen-phen: 5 Questions for 5-HT receptor researcher Bryan Roth [Re: Blue Cthulhu]
    #28476801 - 09/20/23 05:54 PM (7 months, 24 days ago)

I get chest pains when taking for extended periods. I once went too doc 3 hours after a .4 and had a 143/95 pulse. Dose this mean I'll stop no.


--------------------
Had I the heavens' embroidered cloths,
Enwrought with golden and silver light,
The blue and the dim and the dark cloths
Of night and light and the half light,
I would spread the cloths under your feet:
But I, being poor, have only my dreams;
I have spread my dreams under your feet;
Tread softly because you tread on my dreams.

Edited by HappyHigh (09/20/23 05:55 PM)

Extras: Filter Print Post Top
Offlineodissey
Psychonaut
 User Gallery

Registered: 01/19/21
Posts: 489
Loc: Europe
Last seen: 12 days, 1 hour
Re: Heart risks, serotonin, and fen-phen: 5 Questions for 5-HT receptor researcher Bryan Roth [Re: HappyHigh]
    #28572413 - 12/07/23 05:52 AM (5 months, 9 days ago)

Here is a recent review on the topic:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661823/

I believe we should be discussing this topic more. Many people here are doing macrodoses every week believing that at least physiologically it is completely safe.

Last year, I had chest pain and it made me wonder if it was related to my changa/mushroom use. I did an ECG and an echo and both said it was fine, but now that the pain is back I keep wondering. Maybe it is time for a break.


--------------------

Extras: Filter Print Post Top
OfflineTyperwritermonky
shboop a doop a doop


Registered: 01/19/12
Posts: 5,375
Loc: Mrs. Brown's Teahouse
Last seen: 2 months, 26 days
Re: Heart risks, serotonin, and fen-phen: 5 Questions for 5-HT receptor researcher Bryan Roth [Re: odissey]
    #28573089 - 12/07/23 04:46 PM (5 months, 8 days ago)

I've heard Nutt mention this too.  These days I take LSD maybe 6 times a year.  I think that sparse usage will be fine.

I mean it would be great to know just what the risk is, and how the damage works overtime.  Especially with microdosing and how it stimulates those receptors.

As well with all the toxins in the water, microplastics everywhere, toxic building materials, clothes that seep toxins transdermally.. with all the stuff I can't avoid that's going to kill me one day, I think dosing psychedelics a handful of times a year is fine.

But yeah, for what it's worth I know people who took LSD every week for like 5 years.  No issues at all for them many years later, but who knows down the line.

It's something to be mindful of; we don't know what the dangers and risks are, but we know that there is a potential danger and risk over time.

Extras: Filter Print Post Top
Jump to top Pages: 1

Shop: Mushroom-Hut Mono Tub Substrate   PhytoExtractum Buy Bali Kratom Powder   Left Coast Kratom Buy Kratom Extract   Kraken Kratom Kratom Capsules for Sale   North Spore North Spore Mushroom Grow Kits & Cultivation Supplies   OlympusMyco.com Olympus Myco Bulk Substrate


Similar ThreadsPosterViewsRepliesLast post
* Experts debate benefits, risks of hallucinogenic drugs motamanM 2,895 1 12/01/03 06:49 PM
by DailyPot
* [EU] To Hallucinate or Not: The Big Questions Facing Psychedelics at FENS 2022 veggieM 768 1 09/07/22 01:28 PM
by Blue Cthulhu
* Drug drama shocks Splashy Fen rockers motamanM 860 0 04/02/05 01:49 PM
by motaman
* Youths risk death in latest drug abuse trend motamanM 11,247 18 01/27/17 09:32 AM
by Themanwiththeplan
* Laughing gas users risk spinal damage motamanM 2,528 1 04/23/03 07:41 PM
by debianlinux
* Regular cannabis users 'at greater risk of mental illness' Stein 2,711 4 07/06/03 03:14 AM
by Adamist
* Nevada's Question 9 ShroominSpradl 5,494 7 11/06/02 06:38 AM
by bowling-name
* [CAN] Mushroom dispensary raids and “storefront activism”: 5 Questions for Dana Larsen veggieM 1,018 0 12/07/23 03:51 PM
by veggie

Extra information
You cannot start new topics / You cannot reply to topics
HTML is disabled / BBCode is enabled
Moderator: motaman, veggie, Alan Rockefeller, Mostly_Harmless
953 topic views. 1 members, 5 guests and 3 web crawlers are browsing this forum.
[ Show Images Only | Sort by Score | Print Topic ]
Search this thread:

Copyright 1997-2024 Mind Media. Some rights reserved.

Generated in 0.022 seconds spending 0.004 seconds on 12 queries.